Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SphK1-shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
SphK1-shRNA is a short hairpin RNA (shRNA) developed for gene therapy research to specifically silence the expression of sphingosine kinase 1 (SphK1), an enzyme implicated in cancer cell proliferation, survival, and metastasis. By downregulating SphK1, SphK1-shRNA inhibits key signaling pathways such as the STAT3 pathway, resulting in decreased tumor cell proliferation, increased apoptosis, and impaired migration and invasion, particularly demonstrated in neuroblastoma and thyroid cancer models. SphK1-shRNA is commonly delivered using lentiviral vectors in preclinical studies, offering a targeted approach to disrupt sphingolipid metabolism and downstream oncogenic signaling[2][4].
- Other names
- SphK1-shRNASphK-1-shRNASphK 1-shRNAsphingosine kinase 1 shRNA
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)STAT3 (Signal Transducer and Activator of Transcription 3)SPHK1 (Sphingosine kinase 1)GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on SphK1-shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SphK1-shRNA.